Brumbaugh Gordon W
Caine Veterinary Teaching Center,University of Idaho,Caldwell,Idaho,USA.
Anim Health Res Rev. 2014 Dec;15(2):175-7. doi: 10.1017/S1466252314000279. Epub 2014 Nov 20.
Resistance is a qualitative interpretation of antimicrobial activity in vitro. Critical to management of bovine respiratory disease (BRD) is the clinical response in vivo. Attempts to connect activity in vitro to response in vivo have been complicated by the complexity of BRD, interpretation of antimicrobial activity in vitro, and inconsistent measures of clinical success or failure. During recent history, the discovery, development, and commercialization of antimicrobials have decreased. In response to resistance, voluntary and imposed restrictions on use of antimicrobials have been implemented. Resistance can be reversed using technology and knowledge of mechanisms of resistance. Perhaps approaches that reverse resistance will be used in clinical management of BRD in the future. The short answer to the question posed in the title is, 'yes.' Since antimicrobial drugs were discovered, resistance has been a consideration for selection of treatment of any infectious disease and BRD is not unique. In the opinion of the author, the more important question is, 'How will antimicrobial resistance of BRD pathogens impact BRD management in the future?'
耐药性是对抗菌药物体外活性的一种定性解释。对于牛呼吸道疾病（BRD）的管理而言，体内的临床反应至关重要。由于BRD的复杂性、体外抗菌活性的解释以及临床成败衡量标准的不一致，将体外活性与体内反应联系起来的尝试变得复杂。在近代，抗菌药物的发现、开发和商业化有所减少。为应对耐药性，已实施了对抗菌药物使用的自愿性和强制性限制。耐药性可通过耐药机制的技术和知识来逆转。或许逆转耐药性的方法未来将用于BRD的临床管理。标题中问题的简短答案是“是的”。自从发现抗菌药物以来，耐药性一直是选择治疗任何传染病时需要考虑的因素，BRD也不例外。在作者看来，更重要的问题是“BRD病原体的抗菌耐药性未来将如何影响BRD的管理？”
